Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AGG-523 (Aggrecanase Inhibitor)
AGG-523 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | AGG-523 1800 mg QD PO (12 capsules) for 28 days |
| B | ACTIVE_COMPARATOR | AGG-523 900 mg BID PO (12 capsules) for 28 days |
| C | PLACEBO_COMPARATOR | Placebo QD PO (12 capsules) for 28 days |
| D | PLACEBO_COMPARATOR | Placebo BID PO (12 capsules) for 28 days |
| Name | Type | Description |
|---|---|---|
| AGG-523 (Aggrecanase Inhibitor) | DRUG | - |
| AGG-523 | DRUG | - |
Inclusion Criteria: * Generally healthy, men or women, at least 55 years old * Osteoarthritis of the knee requiring total knee replacement surgery Exclusion Criteria: * Other types of arthritis, like rheumatoid arthritis * Recent major surgery (in past 3 months) * Recent knee injections (in past ...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
AGG-523 is an investigational small molecule developed by Pfizer, Inc. (ticker: PFE) for osteoarthritis, a musculoskeletal condition. It is also referred to as AGG-523 (Aggrecanase Inhibitor). The drug has been studied in Phase 1 clinical trials and has not been approved for any use.
AGG-523 was studied for the treatment of osteoarthritis. Its Phase 1 trials enrolled adults with osteoarthritis, including one study in subjects with severe osteoarthritis requiring total knee replacement. The program remains investigational and the drug is not approved for treating osteoarthritis or any other condition.
Pfizer, Inc. (ticker: PFE) is the developer of AGG-523. Pfizer sponsored the Phase 1 clinical studies of the drug in osteoarthritis, all of which were conducted in the United States.
AGG-523 is in Phase 1 development. All three of its recorded clinical trials were Phase 1 studies, and all three are completed, with no active trials ongoing. The drug is investigational and has not received FDA approval.
AGG-523 has been evaluated in three completed Phase 1 trials: NCT00454298 in severe osteoarthritis requiring total knee replacement, NCT00427687 in osteoarthritis, and NCT00380900, a multiple ascending dose study of safety, tolerability, pharmacokinetics and pharmacodynamics in healthy subjects. All were conducted in the United States.
Yes. AGG-523 is also known as AGG-523 (Aggrecanase Inhibitor), so searches for the aggrecanase inhibitor AGG-523 refer to the same Pfizer compound. It is a small molecule studied in Phase 1 trials for osteoarthritis.